Candel Therapeutics (CADL) closed an offering of 12 million shares at $6 apiece and prefunded warrants to raise $92 million in gross proceed.
The warrants are for purchasing up to 3.33 million shares at $5.99 per prefunded warrant to purchase one share of common stock, the company said late Monday in a statement.
The sale includes 2 million shares sold following the full exercise of the underwriters' option.
Candel intends to use the net proceeds to continue the development of its product candidates, including preparing the submission of a biologics license application for CAN-2409 in prostate cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments